Clinical trials
Pathologic Processes trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Odense University Hospital | 2 |
| AstraZeneca | 1 |
| Copenhagen University Hospital at Herlev | 1 |
| Eli Lilly and Company | 1 |
| Grifols Therapeutics LLC | 1 |
| KAI Pharmaceuticals | 1 |
| Novartis Pharmaceuticals | 1 |
| Pfizer | 1 |
| University of Aarhus | 1 |
| University of Washington, the Collaborative Health Studies Coordinating Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pathologic Processes | 13 |
| Lung Diseases | 4 |
| Respiratory Tract Diseases | 4 |
| Genetic Diseases, Inborn | 3 |
| Neoplasms | 3 |
| Postoperative Complications | 3 |
| Cardiovascular Diseases | 2 |
| Digestive System Diseases | 2 |
| Gastrointestinal Diseases | 2 |
| Heart Diseases | 2 |
Trials
Showing 76 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.